{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000017","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.235843+00:00","generated_at":"2026-06-15T17:11:25.493430+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance","bullets":["Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.","Net loss $7M ($0.05 loss per share) vs $2M loss last year; adjusted EPS $0.12 flat YoY.","Adjusted EBITDA $116M, up 16% YoY; company reaffirms full-year 2023 guidance.","Fourth and largest injectables facility successfully inspected; IPX203 PDUFA date June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000017","json":"https://secwatch.observer/filing/0001723128-23-000017.json","markdown":"https://secwatch.observer/filing/0001723128-23-000017.md","text":"https://secwatch.observer/filing/0001723128-23-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/0001723128-23-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/amrx-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T17:11:25.493430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed0be75eb6157aaca8e74998dcb11a85f4484623","claim":"Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $558 million, net income $7 million, EPS $0.05. Guidance reaffirmed.","evidence_excerpt":"Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Year Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/0001723128-23-000017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$558 million"},{"label":"Net income","value":"$7 million"},{"label":"EPS","value":"$0.05"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}